【24h】

Docking for fragment inhibitors of AmpC β-lactamase

机译:对接AmpCβ-内酰胺酶的片段抑制剂

获取原文
获取原文并翻译 | 示例
       

摘要

Fragment screens for new ligands have had wide success, notwithstanding their constraint to libraries of 1,000-10,000 molecules. Larger libraries would be addressable were molecular docking reliable for fragment screens, but this has not been widely accepted. To investigate docking's ability to prioritize fragments, a library of > 137,000 such molecules were docked against the structure of β-lactamase. Forty-eight fragments highly ranked by docking were acquired and tested; 23 had K_i values ranging from 0.7 to 9.2 mM. X-ray crystal structures of the enzyme-bound complexes were determined for 8 of the fragments. For 4, the correspondence between the predicted and experimental structures was high (RMSD between 1.2 and 1.4 A), whereas for another 2, the fidelity was lower but retained most key interactions (RMSD 2.4-2.6 A). Two of the 8 fragments adopted very different poses in the active site owing to enzyme conformational changes. The 48% hit rate of the fragment docking compares very favorably with "lead-like" docking and high-throughput screening against the same enzyme. To understand this, we investigated the occurrence of the fragment scaffolds among larger, lead-like molecules. Approximately 1 % of commercially available fragments contain these inhibitors whereas only 10~(-7)% of lead-like molecules do. This suggests that many more chemotypes and combinations of che-motypes are present among fragments than are available among lead-like molecules, contributing to the higher hit rates. The ability of docking to prioritize these fragments suggests that the technique can be used to exploit the better chemotype coverage that exists at the fragment level.
机译:尽管新配体的片段筛选受到1,000-10,000个分子库的限制,但仍获得了广泛的成功。如果分子对接可用于片段筛选,则较大的文库将是可寻址的,但这尚未被广泛接受。为了研究对接对片段进行优先排序的能力,将大于137,000个此类分子的文库对接β-内酰胺酶的结构。采集并测试了对接排名最高的48个片段; 23的K_i值范围为0.7至9.2mM。确定了其中8个片段的酶结合复合物的X射线晶体结构。对于4,预测结构与实验结构之间的对应关系较高(RMSD在1.2和1.4 A之间),而对于另外2,其保真度较低,但保留了大多数关键交互作用(RMSD 2.4-2.6 A)。由于酶构象变化,8个片段中的2个在活性位点采取了非常不同的姿势。片段对接的48%命中率与“铅样”对接和针对相同酶的高通量筛选相比非常有利。为了理解这一点,我们研究了较大的铅样分子中片段支架的发生。大约1%的可商购片段含有这些抑制剂,而仅10%(-7)%的铅样分子具有这些抑制剂。这表明片段中存在的化学型和化学型组合要比铅样分子多,从而有助于提高命中率。对接对这些片段进行优先排序的能力表明,该技术可用于开发存在于片段级别的更好的化学型覆盖率。

著录项

  • 来源
  • 作者单位

    Department of Pharmaceutical Chemistry, University of California, 1700 4th Street, MC 2550, San Francisco, CA 94158;

    Department of Pharmaceutical Chemistry, University of California, 1700 4th Street, MC 2550, San Francisco, CA 94158 Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404;

    Department of Pharmaceutical Chemistry, University of California, 1700 4th Street, MC 2550, San Francisco, CA 94158;

    Department of Pharmaceutical Chemistry, University of California, 1700 4th Street, MC 2550, San Francisco, CA 94158;

    Department of Pharmaceutical Chemistry, University of California, 1700 4th Street, MC 2550, San Francisco, CA 94158 Genentech, 1 DNA Way, South San Francisco, CA 94080;

    Department of Pharmaceutical Chemistry, University of California, 1700 4th Street, MC 2550, San Francisco, CA 94158;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    crystallography; drug design; hit rates; chemical space;

    机译:晶体学药物设计;命中率;化学空间;
  • 入库时间 2022-08-18 00:41:57

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号